[ Pobierz całość w formacie PDF ]
.G.Farben.The Nazi state became themeans by which cartel agreements were enforced.At left are key Farben defendants at the NurembergWar-Crimes trials.Hermann Schmitz, the mastermind of thecartel, was an integral part of the international bankingstructure.Carl Krauch was chairman of Farben's board ofdirectors.Max llgner, Farben's "Director of Finance," inreality was in charge of espionage and propaganda.OttoAmbros (bottom right) was production chief of Farben'spoison-gas facilities, (us.Army photos)241 John D.Rockefeller, Sr.(above), often gave away shiny dimes tosmall children at public gatherings in an attempt to improve hisimage in the press.This device was suggested by Ivy Lee (left),one of the world's foremost public-relations experts.Mr.Lee alsohad been retained by I.G.Farben to appraise the public-imagePotential of Adolph Hitler.Salter Teagle (above, left), while president of Standard Oil,Secretly held stock in Farben enterprises on behalf of theRockefeller family.Through such ploys, the Rockefellers haveobscured their financial interest in the field of drugs.243 Abraham Flexner (above), author of the famous FlexnerReport of 1910, led the crusade for upgrading the medicalschools of America.All the while, he was in the employ ofAndrew Carnegie (above, left) and John D.Rockefeller (left)who had set up tax-exempt foundations for that purpose.The result was that America's medical schools becameoriented toward drugs and drug research, for it was throughthe increased sale of these drugs that the donors realized aProfit on their "philanthropy." Chapter EighteenTHE CHARITYPRESCRIPTIONThe drug cartel's influence over the nation'smedical schools; the drug-oriented traininggiven to medical students; and the use ofphilanthropic foundations to obtain controlover educational institutions.As we have seen, the Rockefeller group, in conjunction withthe hidden hand of I.G.Farben, has become a dominant force inthe American pharmaceutical industry.One of the consequencesof this reality is that one almost never finds consumer pricecompetition among prescription drugs and patent medicines.Generally, the only competition we see is along the lines of vagueadvertising claims such as "Laboratory tests prove Bayer isbetter," or "Research has shown that Anacin is faster." Over theyears, the pharmaceutical houses have lived up to an agreementto stay within the narrow field of their specialty and to refrainfrom trying to cut into the established markets of their rivals.It is,as they say, an "orderly" industry.One of the reasons for this non-competition is that most drugsare patented and are available only from one manufacturer.Another reason is that the prescription is made by a physicianwho is more concerned with the effectiveness of a drug than withits price.But, in addition, there is the fact that the drug housesbombard the market with so many new drugs each year that theJohn D.Rockefeller, Sr., shown here at age 93, had createdphysician often does not know how effective the drugs are that hefantastic wealth.When he interlocked his own empire withPrescribes.All he knows is that he has seen them advertised in thethat of I.G.Farben in 1928, there was created the largestAMA Journal, has been handed a "fact sheet" by a field repre-and most powerful cartel the world has ever known.Not onlysentative from the company which manufactures them, and mayhas that cartel survived through the years, it has grown anhave had some success with them on previous patients.Becauseprospered.Today it plays a major role in both the sciencehe is a practitioner, not a researcher, he cannot conduct controlledand politics of cancer therapy.experiments to determine the relative effectiveness of the new THE CHARITY PRESCRIPTION 249248 WORLD WITHOUT CANCER: Part Twohas been traced in the preceding pages
[ Pobierz całość w formacie PDF ]